Renaissance Technologies LLC decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 89.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,300 shares of the medical research company's stock after selling 126,300 shares during the period. Renaissance Technologies LLC's holdings in NeoGenomics were worth $212,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the stock. Bellevue Group AG acquired a new position in shares of NeoGenomics in the 1st quarter worth $14,872,000. Kopp LeRoy C acquired a new stake in shares of NeoGenomics during the 1st quarter valued at $14,062,000. Jennison Associates LLC raised its stake in shares of NeoGenomics by 77.8% during the 1st quarter. Jennison Associates LLC now owns 1,051,627 shares of the medical research company's stock worth $16,532,000 after purchasing an additional 460,071 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of NeoGenomics by 7.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,324,624 shares of the medical research company's stock valued at $46,108,000 after purchasing an additional 217,687 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of NeoGenomics by 5.4% in the second quarter. American Century Companies Inc. now owns 3,261,756 shares of the medical research company's stock worth $45,241,000 after buying an additional 167,145 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.
NeoGenomics Stock Down 0.1 %
NASDAQ NEO traded down $0.01 on Friday, reaching $13.53. The company had a trading volume of 1,607,861 shares, compared to its average volume of 825,605. The company's fifty day moving average is $15.64 and its 200-day moving average is $14.84. NeoGenomics, Inc. has a 1-year low of $11.97 and a 1-year high of $21.22. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -20.50 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01.
NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. The company had revenue of $164.50 million for the quarter, compared to analysts' expectations of $161.82 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The business's revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.09) EPS. On average, research analysts forecast that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
NEO has been the topic of several research reports. Benchmark restated a "buy" rating and set a $18.00 price objective on shares of NeoGenomics in a report on Tuesday, September 24th. Stephens reiterated an "overweight" rating and issued a $19.00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reissued a "buy" rating and set a $19.00 price objective on shares of NeoGenomics in a report on Wednesday, September 25th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $19.89.
Check Out Our Latest Report on NeoGenomics
About NeoGenomics
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
